To improve the website's functionality, we use cookies, including third-party cookies. Read our Privacy Policy for more information

I Agree

Gemcitabine HCl Market

Gemcitabine HCl Market By Type (Branded, Generic), By Application (Pancreatic Cancer, Breast Cancer, Ovarian Cancer), By End-user (Hospitals, Cancer Centers) & Region - Global Market Insights 2020 to 2027

Analysis of Gemcitabine HCl market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Gemcitabine HCl Market Outlook (2020-2027)

Consistent R&D in the healthcare industry is offering material benefits to the society, thereby, substantially improving the average life expectancies and quality of living.

In addition, the healthcare vertical is accelerating its shift towards a value-based structure that includes rethinking patient care delivery, cost-effectiveness, and customizing patient experience.

As per the World Health Organization (WHO), cancer causes about 16% of mortalities all over the world, with around 70% of them occurring in low- and middle-income economies (LME).

In the US alone, nearly 90, 000 cancer cases are estimated to be diagnosed in 2020.

This demanding situation is compelling governments all over the world to invest in healthcare system at scale, particularly in oncology research, in a bid to reach a larger patient base.

Against this backdrop, the global gemcitabine HCl market will grow at a healthy CAGR of 6.7% over 2020-2027.

Among the end users, hospitals are expected to capture higher revenue share, while upsurge in oncology research projects in cancer centers are offering new revenue streams.

Don't Need a Global Report?

Save 40% on Country & Region specific reports

Preference for Generic Drugs to Remain Intact

Both, generic and branded drugs exhibit identical efficiency in cancer treatment and contain the same active ingredient.

However, generic drugs emerge as clear winner in terms of cost, as such, and this is garnering huge investments from stakeholders.

Hospitals and cancer research centers are encountering supply shortage of generic injectable drugs in key therapeutic areas such as oncology, and cardiology, a potential opportunity for gemcitabine HCl market players.

Over a third of generic injectable products for cancer treatment are going off-patent by 2020, and the trend is likely to grow over the forecast period. Furthermore, Fact.MR finds that, the value creation of generic drugs will be around thrice that of the branded drugs.

Gemcitabine  market forecast by Fact.MR

North America in Vanguard, APAC to Emerge as Fast-Growing Market

Capturing around 40% of total gemcitabine HCl market stack, North America continues to engage shareholders over the time ahead.

Being a hotbed for innovations in the healthcare sector, favorable reimbursement policies and notable resource allocation to improve healthcare infrastructure are key factors shaping market in the developed region.

Manufacturers are also turning their sights to Asia Pacific (APAC), where the gemcitabine HCl market is expected to flourish at a noteworthy CAGR of over 7%.

In order to curb the expanding cancer patient pool, governments in countries – China, and India – are increasing their per capita healthcare spending.

Furthermore, this study reveals that, the usage of gemcitabine HCl in APAC is likely to surge to about 1.6x through 2027.

Gemcitabine HCl Market

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Market Players Emphasize on Reformulation Strategies to Maintain Competitiveness

R&D projects in the gemcitabine HCl drug market in the recent past have been primarily focusing on advancements in treatment delivery and combination therapy.

High unmet needs and limited efficacy of existing treatments in pancreatic cancer (mostly chemotherapies) have influenced market incumbents to explore better versions of branded gemcitabine agents.

For instance, NuCana Biomed’s Acelarin (NUC-1031), a reformulation of gemcitabine, is in late-stage clinical trials and has been engineered to overcome resistance mechanisms associated with the original drug.

Sun Pharma has launched ready-to-infuse INFUGEM (gemcitabine in sodium chloride injection) in the U.S. INFUGEM - the first chemotherapy product that comes in a premixed formulation.

The reformulation received approval by the U.S. Food and Drug Administration (FDA) in combination with other drugs for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent for the treatment of pancreatic cancer.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Gemcitabine HCl Market: In-Depth Analysis on Key Segments

Fact.MR has studied the gemcitabine HCl market with detailed segmentation on the basis of type, application, end users, and key regions.


  • Branded
  • Generic


  • Pancreatic Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Non-small-cell lung carcinoma (NSCLC)
  • Others

End Users

  • Hospitals
  • Cancer Centers
  • Others


  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

The Fact.MR study covers country-specific analysis on demand for gemcitabine HCl for each regional market in tandem with the market size valuation and projected price point analysis, price index, and impact of major regional and country-wise dynamics, which were gathered via quotes from several gemcitabine HCl manufacturers, experts, and suppliers.

The study also provides Y-o-Y growth projections on every regional market covered. Further, future trends, growth opportunities, and other factors associated with the market have been elaborated in the study.

The report offers company-level market share assessment, which has been deduced based on the company’s yearly sales and segmental revenue in every target end-use sectors.

The market has been projected on the basis of constant currency rates. The report also offer detailed competitive and company profiles of key participants running in the global gemcitabine HCl market.

Some of the major competitors operating in the robot process automation market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord-UK Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd., Ingenus Pharmaceuticals, and others.

- Premium Report Details -

Gemcitabine HCl Market
  • FACT4646MR
  • Mar-2022
  • Healthcare
  • 170 Pages
  • 92 Tables
  • 91 Figures

- Let's Connect -

Talk To an Expert Today Connect

- Get Started -

Get insights that lead to new growth opportunities

Buy Now

Get A Special pricing for start-ups and universities

Enquiry Before Buying

- Humble, Yet Honored -

Our prestigious clients

- Research Methodology -

An Adaptive Approach to Modern-day Research Needs

Get Methodology

- FAQs -

Gemcitabine HCl Market Experiences Healthy 6.7% Growth through 2027.

The global Gemcitabine HCl market is segmented on the basis of type, application, end users, and key regions.

The Prominent manufacturers covered: Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord-UK Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd., Ingenus Pharmaceuticals.

Exclusive Report

Need An Exclusive Report For Your Unique Requirement?

Google translate